- Home
- PLRX
as 11-15-2024 4:00pm EST
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | SOUTH SAN FRANCISCO |
| Market Cap: | 641.5M | IPO Year: | 2020 |
| Target Price: | $40.50 | AVG Volume (30 days): | 418.7K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 7 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -3.34 | EPS Growth: | N/A |
| 52 Week Low/High: | $10.22 - $19.62 | Next Earning Date: | 11-07-2024 |
| Revenue: | N/A | Revenue Growth: | -83.69% |
| Revenue Growth (this year): | -71.76% | Revenue Growth (next year): | 585.71% |
Latest Pliant Therapeutics Inc. News
PLRX Breaking Stock News: Dive into PLRX Ticker-Specific Updates for Smart Investing
GlobeNewswire
10 days ago
Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2024 Financial Results
GlobeNewswire
11 days ago
Pliant Therapeutics to Participate in the Stifel Healthcare Conference
GlobeNewswire
a month ago
Pliant Therapeutics INTEGRIS-PSC Phase 2a Data Evaluating Bexotegrast in Primary Sclerosing Cholangitis to be Highlighted in a Late-Breaking Presentation at The Liver Meeting® 2024
GuruFocus.com
a month ago
Paradigm Biocapital Advisors LP Acquires New Stake in Pliant Therapeutics Inc
GlobeNewswire
2 months ago
Pliant Therapeutics Appoints Gary Palmer, M.D. as Senior Vice President of Medical Affairs
GlobeNewswire
2 months ago
Pliant Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire
2 months ago
Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
GlobeNewswire
2 months ago
Pliant Therapeutics Presents Data from its Bexotegrast Program at the European Respiratory Society International Congress 2024
Compare PLRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "PLRX Pliant Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.